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Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, United StatesSummary [1–13]. Reasons to tightly monitor ﬁbrosis progression after liverLiver ﬁbrosis results from an excessive wound healing response
in most chronic liver diseases, such as hepatitis C. Despite great
advances in antiviral therapy in recent years, progressive liver
ﬁbrosis remains a major problem for patients with recurrent hep-
atitis C after liver transplantation. Liver biopsy remains a central
tool in the management of HCV-positive liver transplant recipi-
ents, but reliable non-invasive methods for the assessment of
liver ﬁbrosis, such as ultrasound elastography, are increasingly
being incorporated in the management of post-transplant
patients, helping predict prognosis, guide treatment decisions,
and stratify patients for emerging antiﬁbrotic therapies.
In this manuscript, we will review the natural history as well as
tools to monitor ﬁbrosis progression in the HCV-positive liver
transplant recipient, the mechanisms underlying rapid ﬁbrosis
progression in up to 30% of these patients, the effect of antiviral
therapies and highlight promising antiﬁbrotic approaches.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Fibrosis progression monitoring: justiﬁcation and tools
Natural history of ﬁbrosis progression in post-transplant hepatitis C
The deposition of ﬁbrotic tissue in most HCV transplanted livers
is highly accelerated with development of bridging ﬁbrosis and
cirrhosis in 20–54% at 5 years and 32–51% at 7 years (Table 1)Journal of Hepatology 20
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 CIBEREHD is funded by the Instituto de Salud Carlos III.transplantation include: (i) poor correlation between liver func-
tion tests and histology, both in HCV and non-HCV recipients
[1–4,14,15]; in one recent study where 165 biopsies were taken
at the time of normal liver function tests, histologic abnormalities
were found in almost one third of biopsies (11.5% of which were
considered to be clinically signiﬁcant), including fatty liver dis-
ease, low-grade/low-stage recurrent hepatitis C or primary biliary
cirrhosis, or central venulitis [16]; (ii) the usually high speed of
ﬁbrosis progression in transplant compared to non-transplant
patients, with medium annual rates ranging from 0.2 to 0.8 Meta-
vir stages/year (Table 2) [1,2,10,12,17–23] compared to 0.1–0.2 in
non-transplanted, immune competent patients [24]. Moreover,
ﬁbrosis progression often is not linear [19,20] and can have an
early exponential increase [12,21,25] as well as a late start [26].
In fact, the lack of linearity was recently conﬁrmed by a non-Mar-
kov analysis based on 901 histological ﬁbrosis assessments in 401
patients [27]. Moreover, this model showed that the risk of pro-
gression decreased as time spent at a given ﬁbrosis stage
increased, however, a longer time to reach that stage did not pre-
dict risk of progression to a higher stage. In other words, this indi-
cates that disease activity is variable over time and that current
time at a given stage rather than the prior time in earlier stages
is most predictive of future progression [27]; (iii) the potential
to predict outcome. Indeed, the course of progression appears
to be determined early after transplantation [28,29], and the
stage of ﬁbrosis within the ﬁrst year has been shown to be
strongly associated with subsequent progression to cirrhosis as
well as with graft and patient survival. Additional information
that can be used to predict the risk of ﬁbrosis progression
includes the degree of necroinﬂammation in early biopsies, the
age of the donor, viral load, the degree of immunosuppression
as well as concurrent complications occurring during the ﬁrst
months post-transplantation, mainly biliary complications [1,2].
In particular, the degree of necroinﬂammation helps identify
those at increased risk of ﬁbrosis progression and with impaired
survival [1–5,9,10,21,22,30–34] (Table 3A and B). Overall,
patients in whom at least moderate ﬁbrosis (Metavir F P2) is
found in the ﬁrst-year have a signiﬁcantly greater risk of pro-
gressing to cirrhosis and a lower graft and patient survival than
those with minimal or absent ﬁbrosis; (iv) limited efﬁcacy but
high toxicity of antivirals in transplant recipients [35–44] (see13 vol. 58 j 1028–1041
Table 1. Progression to bridging ﬁbrosis or cirrhosis in HCV-infected liver transplant recipients.
Author, yr [Ref.] n Outcome measure 3 yr outcome 5 yr outcome 7 yr outcome
Gane et al., 1996 [3] 149 Cirrhosis 20%
Prieto et al., 1999 [4] 81 Actuarial rate of cirrhosis 16% 28%
Sreekumar et al., 2000 [5] 47 F ≥2 47%
Sanchez-Fueyos et al., 2002 [7] 134 Actuarial rate of graft damage 15% 33% 44%
Berenguer et al., 2002 [6] 189 Actuarial risk of cirrhosis 25% 44% 51%
Wali et al., 2003 [8] 49 24% non-GT4 
vs. 85% GT4
Neumann et al., 2004 [9] 183 Cirrhosis or death 17% 25% 24%
Yilmaz et al., 2007 [10] 227
Cirrhosis
11%
2%
25%
6%
41% 
10%
Belli et al., 2007 [11] 354 18% 27% 32%
Walter et al., 2007* [12] 105 18% at a mean 
of 4.7 yr
Lai et al., 2011 [13] 1264 38% for women 
33% men
54% for women 
45% men
(cirrhosis + FCH + submassive liver fibrosis)
Severe fibrosis (F5-6)
Bridging fibrosis or cirrhosis
Bridging fibrosis or cirrhosis
Bridging fibrosis or cirrhosis
Bridging fibrosis or cirrhosis
⁄Surviving the ﬁrst year, 67% having received early antiviral therapy.
FCH, ﬁbrosing cholestatic hepatitis; yr, year.
Table 2. Fibrosis progression rates described in liver transplant recipients infected with HCV.
Author, yr [Ref.], n 1 yr FPR 3 yr FPR 5 yr FPR 6-10 yr FPR
Berenguer et al., 2000 [20], n = 284 0.3 FU/yr Time to F ≥1: 2-2.3 yr
Time to F ≥2: 4.5-4.7 yr
Time to F ≥3: 5.9-6 yr
Time to F4: 9.5-11.6 yr
Wali et al., 2002 [19], n = 56 0.78 FU/yr
DA <40 yr: 0.6 FU/yr
DA >50 yr: 2.7 FU/yr
Time to F4: 7.7 yr
10 yr
2.2 yr
Neuman et al., 2004 [21], n = 183 1.2 FU/yr 0.25 FU/yr 0.08 FU/yr
Firpi et al., 2004 [22], n = 264 0.8 FU/yr
Walter et al., 2007 [12], n = 105 0.33 FU/yr 0.33 FU/yr 0.16 FU/yr 0.08 FU/yr
Selzner et al., 2008 [23], n = 201 0.19 FU/yr in DDLT vs. 0.11 FU/yr in LDLT
FU, units of ﬁbrosis (Metavir scale); yr, year; FPR, ﬁbrosis progression rates; DA, donor age; DDLT, deceased-donor liver transplantation; LDLT, live-donor liver
transplantation.
JOURNAL OF HEPATOLOGYsection on antiviral therapy). The discrimination between
patients with slow and rapid ﬁbrosis progression would avoid
starting unnecessary antiviral therapy in patients with an
expected good long-term survival, while urging early treatment
in those at high risk of disease progression; (v) improved efﬁcacy
and reduced toxicity if antiviral therapy is started at less
advanced stages of ﬁbrosis, particularly before the development
of cirrhosis [40–44]. This is exempliﬁed by a single center study,
where lower sustained viral response (SVR) rates were achieved
by recipients treated during a more recent period of time
(2001–2005: n = 71, 42% vs. 2006–2007: n = 36, 24%; p = 0.043).
One likely explanation is the greater proportion of patients trea-
ted at advanced stages, which is associated with lower rates of
viral clearance. Most speciﬁcally, of 22 patients with baseline cir-
rhosis, only 4 (18%) achieved SVR, whereas 34 out of 83 (41%)
non-cirrhotic patients reached an SVR [43]. Increased SVR ratesJournal of Hepatology 2013(from 25% to 54%) were later achieved in the same center after
treatment policy was changed to start therapy at lower ﬁbrosis
stages (the number of cirrhotic patients decreased from 20.5%
to 7%) coupled with higher ribavirin doses [44]. Others showed
that among 113 patients with a 38% SVR rate, tolerability of ther-
apy decreased signiﬁcantly in those with ﬁbrosis stage P3 at
baseline liver biopsy. A total of 20% of the advanced patients died
or were re-transplanted due to liver failure as opposed to 1% of
patients with ﬁbrosis stage <3 [40]. Whether the same will hold
true in the era of new direct oral antivirals remains to be seen;
(vi) potential co-existence of other lesions, some of which should
be excluded before initiating antiviral therapy with interferon-
based regimes, such as rejection or autoimmunity [32,33,35,36].
In a recent study, autoimmune features (mainly plasma cell hep-
atitis) in liver biopsies collected before peg-interferon therapy
were one of the main risk factors for the development ofvol. 58 j 1028–1041 1029
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interferon related severe immune-mediated graft dysfunction,
characterized by overt plasma cell hepatitis or rejection [35].Key Points
• Fibrosis progression is accelerated in recurrent hepatitis
C with 20% to 54% of liver transplant recipients 
developing bridging fibrosis-cirrhosis within the first 5
years post-transplantation
• Chronic hepatitis C can be considered “a wound that
does not heal”, with persistent low level inflammation
and an immune response that favors replacement of
functional liver by scar tissue; co-morbidities, frequently
present in HCV-liver transplant recipients, such as 
insulin resistance or hepatotoxic medications, further
promote this abnormal reparative response which often
results in early advanced graft fibrosis and cirrhosis
• Due to the accelerated nature of fibrosis progression
in recurrent hepatitis C, frequent assessment of liver
fibrosis is essential, particularly to indicate timely 
antiviral therapy
• Transient elastography is a reliable non-invasive 
alternative to liver biopsy that can be repeated serially
to determine the degree of liver fibrosis in recurrent
hepatitis C
• Antiviral therapy post-transplantation results in greater
sustained viral eradication and lesser frequency of 
complications if started at mild stages of fibrosis 
• Fibrosis stabilization or regression in those with 
sustained viral response is usually only observed in
subsequent “long-term biopsies”Tools to monitor ﬁbrosis progression after liver transplantation
Liver biopsy hepatic venous pressure gradient (HVPG) measurement
In order to monitor ﬁbrosis progression, most Consensus Confer-
ences [1,2] have strongly recommended the performance of pro-
tocol liver biopsies at variable time intervals, a practice that is
widely accepted by many, though not all transplant teams [14].
The ideal interval between biopsies is not settled but given the
compressed natural history of recurrent hepatitis C, some authors
have advocated yearly intervals. Several histological scores are
used with no evidence of superiority of one of them [32,33]. Add-
ing measurement of the HVPG can improve diagnostic accuracy,
particularly identifying patients at high risk of hepatic decom-
pensation. In one study, HVPG P6 mmHg 1 year post-transplan-
tation identiﬁed 12 (80%) of the 15 patients with severe
recurrence, whereas only nine (60%) of these had signiﬁcant
ﬁbrosis (F P2) in the 1st year biopsy [45]. In a second study, 4
of 13 (31%) recipients with portal hypertension (HVPG
P6 mmHg) decompensated compared to none of 29 without por-
tal hypertension [46]. A close correlation between the stage of
ﬁbrosis and HVPG was described in both studies, and discrepant
results were mostly attributed to biopsy sampling variability and
speciﬁc histological features, such as perisinusoidal ﬁbrosis,
rather than errors in measuring HVPG.1030 Journal of Hepatology 2013Despite its undisputed value, biopsy has limitations in the
liver transplant population, as widely demonstrated in non-
transplanted patients. It is an invasive tool with a small but none-
theless existent risk of morbidity and mortality, and not always
accepted by transplant recipients. The estimated rate of major
complications is 0.6%, with a mortality rate of 0.02%. Further-
more, errors in staging ﬁbrosis occur as a result of sampling var-
iability, particularly with needle biopsies of insufﬁcient length.
Finally, lack of experience with graft biopsy interpretation may
result in a wrong assessment of ﬁbrosis stage [47].
Liver biopsy remains the ‘‘tarnished’’ gold standard against
which the different tests (see below) are compared to assess
ﬁbrosis. Apart from sampling variability, the traditional assess-
ment of histology is based on semiquantitative categorical stag-
ing systems (METAVIR > Ishak > Sheuer) which in itself is
insufﬁcient to accurately measure the extent of scar tissue depo-
sition [32,33,47,48]. An alternative method to quantify ﬁbrosis in
liver biopsies is digital image analysis of picrosirius red stained
sections to determine the collagen proportionate area (CPA)
[49]. In 115 liver transplant recipients with HCV recurrence,
CPA was superior to Ishak staging and strongly correlated with
HVPG [49]. In addition, in 135 patients transplanted for HCV cir-
rhosis, CPA at 1 year predicted clinical decompensation with
good sensitivity (82%) and speciﬁcity (95%), again being superior
to Ishak scoring, but also to HVPG [50]. As CPA is a continuous
variable, it is expected to represent a more exact histologic mea-
sure of scar tissue deposition than staging, although it is equally
prone to sampling variability.
Non-invasive assessment of graft ﬁbrosis
As in the non-transplant setting, non-invasive tools for the
assessment of liver ﬁbrosis and ﬁbrogenesis are much needed
[51]. Ideally, these should be simple, cheap, easy to perform, safe,
precise, reproducible, and capable of differentiating patients at
need of therapy (ﬁbrosis Metavir 1), especially those with bridg-
ing ﬁbrosis and cirrhosis who are at risk of developing severe
complications. The current tools are roughly divided into 2
groups: (i) direct (related to scar tissue components) or indirect
(related to liver function) serum biomarkers or their combina-
tions to assess ﬁbrosis stage, and possibly ﬁbrosis progression
[51–63]; and (ii) imaging techniques such as ultrasound and
magnetic resonance elastography (ﬁbroscan) and acoustic radia-
tion force imaging (ARFI) [56,57,64–75]. Among non-invasive
tools, ultrasound elastography is the one that has most exten-
sively been evaluated in HCV-infected liver transplant recipients.
Serum markers. Direct serummarkers result from the turnover of
extracellular matrix components that are released into the
circulation. While they have a higher biological plausibility than
indirect markers (which are mainly related to liver inﬂammation
and function), most direct tests are expensive and not always
available for routine use. Furthermore, they have only been eval-
uated in few studies [59,61–63]. One study used an algorithm of
three direct markers (3-M-ALG) [59], i.e., hyaluronic acid (HA),
the N-propeptide of type-III-procollagen (PIIINP) and tissue
inhibitor of matrix metalloproteinase-1 (TIMP-1). The 3-M-ALG
was measured in sera of 133 HCV positive patients at 3, 6, and
12 months post-transplant. Notably, at 12 months, 50 patients
(38%) had signiﬁcant ﬁbrosis (F P2) and 31 (32%) an HVPG
P6 mmHg. The 3-M-ALG at 6 months identiﬁed most patients
with mild ﬁbrosis (NPV 79%) and normal portal pressure (NPVvol. 58 j 1028–1041
Table 3. Association between the one-year liver biopsy results and outcome in HCV-infected liver transplant recipients. (A) Association between ﬁrst year
necroinﬂammation and outcome in HCV infected liver transplant recipients. (B) Association between initial ﬁbrosis and outcome in HCV-infected liver transplant recipients.
A
Author, yr [Ref.] Time of liver biopsy HAI grade Outcome measure Outcome
Gane et al., 1996 [3] 1 yr Mild
Moderate-severe
5%
62%
Prieto et al., 1999 [4] 1 yr Mild
Moderate-severe
7%
28%
Sreekumar et al., 2000 [5] 4 mo <3
>3
0.9
2.3
Guido et al., 2002 6 mo 4 (1-8)
11 (9-14)
3 yr cirrhosis No
Yes
Neumann et al., 2004 [21] 1 yr ≥2 Cirrhosis Risk increased x5.3
Firpi et al., 2004 [22] 1 yr Mild
Moderate-severe
10%
36%
Yilmaz et al., 2007 [10] 1 yr Mean Knodell score
1.5
2.5
Cirrhosis
No
Yes
B
Author, yr [Ref.] Time of liver biopsy Fibrosis stage Outcome measure Outcome
Prieto et al., 1999 [4] 1 yr F = 0
F ≥1
5 yr cirrhosis 8.6%
27%
Berenguer et al., 2003 [26] 3 yr F0 + normal ALT
F0 + high ALT
F1 + normal ALT
F1 + high ALT
Delayed onset liver disease 6%
22%
50%
71%
Firpi et al., 2004 [22] 4 mo
1 yr
F0-1
F2-3
F0-1
F2-3
5 yr Ishak F5-6 12%
26%
11%
21%
Neumann et al., 2004 [9] 1 yr F0
F1-2
F3-4
5 yr survival 93%
90%
60%
Walter et al., 2007 [12] Any time F <3
F3-4
10 yr survival 87%
63%
Gallegos-Orozco et al., 2009 [25] 1 yr F1
F ≥2
Mortality rate 5.5%
25.6%
Meridien et al., 2010 [31] 1 yr F0
F ≥1
Fibrosis progression No or little
Persistent 
progression
5 yr bridging fibrosis or cirrhosis
5 yr bridging fibrosis-cirrhosis
3 yr mean fibrosis stage
5 yr bridging fibrosis or cirrhosis
ALT, alanine aminotransferase; yr, year; mo, month; HAI, hepatic activity index.
JOURNAL OF HEPATOLOGY90%) one year after transplant. It also predicted portal hyperten-
sion one year after transplantation with a very good AUC of 0.9,
and signiﬁcant ﬁbrosis with an AUC of 0.78, being superior to
the AST/ALT ratio, APRI or Benlloch indices [59]. Importantly, 3-
M-ALG at 12 months was able to identify most patients at risk
of decompensation or death; such that a 12-month 3-M-ALG
P2 identiﬁed 59% of patients that presented clinical decompen-
sation and 65% of patients who died due to hepatitis C recurrence
during a median follow-up of 58 months. Based on these data, the
authors suggested that in patients with a 3-M-ALG P2.9 at
6 months, antiviral treatment should be initiated early, since
89% in this group developed portal hypertension at one year. In
contrast, in those with a 3-M-ALG P1.6, mere follow-up would
be appropriate, since 90% in this group showed minimal disease
progression [59].
In another study, 46 patients underwent liver biopsy 4 and
40 months post-transplantation. Rapid ﬁbrosis progression, asJournal of Hepatology 2013deﬁned as an increase P2 Ishak ﬁbrosis stages, could be pre-
dicted by baseline levels of HA and YKL-40 [62], better than by
transaminases, histologic activity index or histological ﬁbrogenic
activation, as assessed by staining for a-smooth muscle actin.
However, limitations of this study are low numbers of patients,
a too long duration between biopsies to clearly separate rapid
as opposed to slow ﬁbrosers, and the lack of a non-HCV control
group to conﬁrm that the increase in levels of HA and YKL-40
at 4 months was unrelated to early insults such as graft perfusion,
biliary complications, other viral infections or rejection episodes.
Finally, in 90 patients followed for a median period of 3 years,
serum levels of CXCL10, a chemokine that is implicated in exper-
imental liver ﬁbrosis, when measured 6–9 months after trans-
plantation, were strongly associated with early ﬁbrosis
recurrence independently of risk confounders, such as donor
age or acute rejection [63]. In multivariate analysis, CXCL10
serum levels 6140 pg/ml predicted absence of signiﬁcant (Fvol. 58 j 1028–1041 1031
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P2) ﬁbrosis, and levels 6220 pg/ml predicted the absence of F3
ﬁbrosis at 3 years.
Several algorithms using indirect markers have been proposed
for monitoring patients after liver transplantation [52–55,73].
Their applicability is limited, since some of their constituent
parameters are altered in liver transplant recipients by factors
unrelated to HCV infection; for instance, (i) cholesterol levels
often increase due to immunosuppressive drugs, (ii) the platelet
count may remain low due to the persistence of splenomegaly,
and (iii) elevated GGT levels may result from mechanical biliary
complications. In the ﬁrst study [53], the authors examined the
predictive value of prothrombin time (PT), albumin/protein ratio,
AST level and time from liver transplant (TFLT) in 510 yearly pro-
tocol biopsies from 188 HCV-positive liver transplant recipients,
using a training and validation set. They thus created the HULF
score (or Benlloch index) which predicted signiﬁcant ﬁbrosis (F
P2) with an area under the curve (AUC) of 0.8 in the training
set and of 0.84 in the validation set. A cut-off of 0.2 yielded
95% accuracy for the exclusion of signiﬁcant ﬁbrosis, while a
cut-off of 0.8 had an 80% positive predictive value for signiﬁcant
ﬁbrosis [53]. However, in a prospective cohort of 93 biopsies, the
AUC fell to 0.68 with a negative predictive value (NPV) and a
positive predictive value (PPV) of 88% and 48%, respectively, for
the same cut-offs [54]. The London Transplant Score was devel-
oped as a modiﬁcation of the King’s College Score in a retrospec-
tive study that involved 185 patients [55]. The score includes
platelets, INR, AST TFLT, and showed an AUC of 0.82 for F P3
using the Ishak classiﬁcation, superior to APRI (AST-to-platelets
ratio index). Other authors have evaluated how scores validated
in immune competent patients perform in HCV-infected liver
transplant patients [56,57]. In one study, APRI ([(AST/upper limit
NV AST)  100]/number of platelets (109/l)), Bonacini’s index
(different points given (which are added together) according to
the value of AST/ALT, INR and platelet count) and Forns score
(7.811  3.131  ln[number of platelets (109/l)]  0.781ln[GGTP
(U/L)] + 3.467  ln[age (years)]  0.014 [cholesterol (mg/dl)]
were compared with ﬁbrosis stage in 102 biopsies from 51
HCV-infected liver transplant recipients. APRI had the best diag-
nostic accuracy, with AUC 0.8, PPV 46%, and NPV 93% [52], indi-
cating that none of these scores may be a reliable predictor of
stage in liver transplant recipients.
The use of artiﬁcial neural networks, a learning system based
on a computational technique that has been used to simulate the
neurological processing ability of the human brain, and hence a
technique that works better than logit models in complex biolog-
ical situations, may provide a better prediction of the presence or
absence of signiﬁcant ﬁbrosis using routine laboratory tests, but
due to their complexity they have not found wide application
[58]. Importantly, prospective studies have shown the superiority
of transient elastography over these methodologies [56,66,69,70].
Imaging techniques. Imaging techniques are increasingly gaining
importance to assess ﬁbrosis post-liver transplant. A combination
of imaging and a mechanical measurement is the determination
of liver tissue stiffness (measured in kilopascals, kPa) by ultra-
sound or MR elastography. Ultrasound elastography (UE) corre-
lates well with ﬁbrosis stage and HVPG, as shown in studies of
transplants from cadavers and living donors [56,64–72]. The ﬁrst
study included a cohort of 124 HCV recipients that underwent
169 liver biopsies and 129 hemodynamic studies [64]. There
was an excellent correlation between histological ﬁbrosis stage1032 Journal of Hepatology 2013and liver stiffness, with an AUC for diagnosis of signiﬁcant ﬁbro-
sis (FP2) and portal hypertension (HVPGP6 mmHg) of 0.90 and
0.93, respectively. Using a cut-off value of 8.7 kPa, sensitivity and
negative predictive value for signiﬁcant ﬁbrosis and portal hyper-
tension were >0.90 in all cases, and none of the few cases with
liver stiffness below the cut-off value and signiﬁcant histological
ﬁbrosis displayed bridging ﬁbrosis or cirrhosis. Similarly, only
few cases with liver stiffness below the cut-off value had portal
hypertension and, importantly, none of them had signiﬁcant por-
tal hypertension (HVPG P10 mmHg). Several additional studies
and two systematic reviews have conﬁrmed these initial results
[56,65–72]. Based on all these studies, the cut-off values for
detection of patients with ﬁbrosis F P2 vary between 7.9 and
10.1 kPa, all of them with high positive (65–86%) and negative
predictive values (88–94%). For cirrhosis, the cut-off values in
cadaver donor transplants have ranged from 12 to 12.5 kPa with
50–74% and 99–100% PPV and NPV, respectively, while in living
donors PPV and NPV of 83% and 100%, respectively, were reported
for a cut-off of 26.5 kPa [70,71]. Importantly, repeat elastogra-
phies can identify patients with signiﬁcant ﬁbrosis (F P2) or
HVPG >6 mmHg as soon as 6 months after transplantation, reach-
ing an excellent diagnostic performance at 12 months. Thus med-
ian liver stiffness at 6, 9, and 12 months post-transplant was
signiﬁcantly higher in rapid ﬁbrosers (9.9, 9.5, and 12.1 kPa,
respectively) than in slow ﬁbrosers (6.9, 7.5, 6.6 kPa) (p <0.01
all-time points) [72]. A mathematical model, adding serum biliru-
bin and donor age to the stiffness value, further improved its
capability at 6 months to identify high-risk patients. Finally, the
utility of MR elastography was recently shown in 32 patients
with recurrent hepatitis C post-transplant [75]. When MRE was
compared to FIBROSpectII (an algorithm of serum a2M, PIIINP
and TIMP-1) AST:ALT ratio, and APRI, both MRE (p = 0.0001,
AUC 0.87) and FIBROSpectII (p = 0.009, AUC 0.84) were signiﬁ-
cantly different between patients with no ﬁbrosis and F P1,
whereas APRI and AST:ALT ratios had no discriminative power.
An MRE cut-off of 3.81 kPa had 87.5% sensitivity, 79.2% speciﬁc-
ity, 58.3% PPV, and 95.0% NPV for detection of FP1. These results
need to be reproduced in a larger cohort, and compared with
transient elastography.
A prospective study assessed the predictive accuracy of ultra-
sound elastography with 4 non-invasive tests (APRI, Forns, Benl-
loch and the Doppler resistance index) in 56 patients (F1 = 38 vs.
F2 = 9, F3 = 8, F4 = 1; n = 36 with all clinical-serological indices)
[66]. Ultrasound elastography provided the best accuracy in
identifying patients with signiﬁcant (F P2) ﬁbrosis. A stiffness
cut-off of 10.1 kPa had 94% sensitivity, 89% speciﬁcity, 81% PPV
and 94% NPV in differentiating F1 from F2–F4. The AUC (0.943)
was greater than that of the other non-invasive indices (APRI:
0.815, Benlloch: 0.799, Splenic Doppler: 0.784; Forns: 0.710,
Fibrotest: 0.562; p <0.01). Comparisons between non-inva-
sive tests performed in other studies have all shown better per-
formance for UE [56,70,71]. In fact, in the most recent meta-
analysis, the authors conclude that UE has excellent diagnostic
accuracy for identifying post-transplant HCV cirrhosis and that
detection of F2–F4 ﬁbrosis is more accurate in patients post-
transplant than in non-transplanted patients with HCV infection
[71].
In summary, non-invasive tools in HCV-infected liver trans-
plant patients should be used as a complement to liver biopsies
(Fig. 1). Liver biopsies should always be performed prior to anti-
viral therapy to assess the degree of necroinﬂammation and addi-vol. 58 j 1028–1041
Recurrent HCV
Liver transplantation
Cholestatic hepatitis
Follow-up
Fibroscan ± serum markers/3-6 months
First year liver biopsy ± HVPG
Stable near/normal ALT
Fibroscan <8 kPa
Benlloch index Z <1386
3-MALG <2
F = 0 or F = 1 + mild HAI
HVPG <6 mmHg
Fibroscan >8 kPa
Benlloch index >1386
3-MALG ≥2
F = 2-4 or F = 1 and moderate-severe HAI
HVPG >6 mmHg
Antiviral therapy
Antiviral therapy
Fig. 1. Algorithm for disease monitoring in HCV infected liver transplant
recipients. 3-MALG, algorithm combing 3 biomarkers; HAI, hepatic activity
index; ALT, alanine aminotransferase; HVPG, hepatic venous pressure gradient.
JOURNAL OF HEPATOLOGYtional pathologies, or hepatic comorbidities such as fatty liver.
Non-invasive tests, particularly transient elastography, are use-
ful: (i) to create a baseline at the time of ﬁrst post-transplant liver
biopsy, and (ii) to better assess the risk of ﬁbrosis progression,
especially as an easy-to-perform test to be done serially between
(less frequent) biopsies [57]. We suggest that protocol liver biop-
sies can be avoided in cases of stable liver blood tests, stable liverQuiescent
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Molecular mechanisms of accelerated ﬁbrosis progression in
post-transplant hepatitis C
Liver ﬁbrosis and cirrhosis
Liver ﬁbrosis results from an excessive wound healing response in
most forms of chronic liver diseases. When ﬁbrogenesis (scar tis-
sue deposition) remains unbalanced by ﬁbrolysis (scar tissue
removal), patients progress to cirrhosis, which is characterized
by a distortion of the liver architecture and represents the major
determinant of morbidity and mortality in patients with chronic
liver disease [76]. The major scar producing cells in the liver are
myoﬁbroblasts that derive from either activated hepatic stellate
cells (HSC), or portal or perivascular ﬁbroblasts [76–79]. Myoﬁbro-
blast activation is mainly driven by ﬁbrogenic chemokines and
cytokines that are released by subclasses of macrophages (likely
alternatively activatedM2macrophages), other inﬂammatory cells,
apoptotic hepatocytes or activated bile duct epithelia that resem-
ble progenitor cells [80–82] (Fig. 2). Notably, due to the close inter-
action of HSC with sinusoidal endothelial cells and macrophages
(Kupffer cells), ﬁbrogenesis and the development of cirrhosis are
tightly linked to intrahepatic angiogenesis and vascular changes
[82]. Many of the cells, factors and signalling pathways in ﬁbrosis
and pathological angiogenesis have been characterized thoroughly
in the last few years [76–82], representing attractive targets for
speciﬁc antiﬁbrotic therapies (see below).
Fibrogenic activities of HCV
HCV elicits direct and indirect proﬁbrogenic responses apart from
ﬁbrogenesis induced by chronic inﬂammation and a continued
would healing response (see the following paragraph). Several
earlier studies that have described the pro-apoptotic, steatosis-Fibrotic liver
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Frontiers in Liver Transplantationinducing and cancerogenic effects of HCV core protein and non-
structural protein 5A (NS5A) which had been summarized before
[83]. Both proteins but also incomplete and complete HCV repli-
cons have been shown to interact with regulators of cell prolifer-
ation, lipid metabolism, oxygen handling, or apoptosis in cell
cultures and transgenic mouse models [83–89]. Notably, HCV
infection and hepatic steatosis are associated, and patients with
chronic hepatitis C have a higher prevalence of insulin resistance
and type 2 diabetes than matched patients with other chronic
liver diseases [85,90–92]. Consumption of even low amounts of
ethanol, another ‘‘second hit’’, is contributory [93–97]. Since
resultant hepatocyte steatosis, insulin resistance, and apoptosis
are implicated as important drivers of ﬁbrogenesis, these pathol-
ogies clearly enhance ﬁbrosis progression in patients with
chronic hepatitis C [97–101].
There is also evidence ofmore direct proﬁbrogenic effects ofHCV.
Thus HuH7 hepatoma cells that propagate the NS3-NS5 replicon,
release proﬁbrogenic factors, mainly active TGFb1 that induces pro-
ﬁbrogenic and suppresses ﬁbrolytic genes and proteins in HSC and
myoﬁbroblasts [102], aneffect that is also inducedbyHCVcorealone,
which is not present in the NS3–NS5 replicon [103]. Moreover, HCV-
E2 protein has been implicated in ﬁbrogenesis, since it induces pro-
ﬁbrogenic matrix metalloproteinase (MMP)-2 in HSC [104]. These
studies suggest that high HCV replication alone, irrespective of the
HCV-induced chronic immune response, plays a role in ﬁbrosis pro-
gression, a hypothesis which is relevant for post-transplant HCV
infection when HCV levels are usually high.
HIV co-infection is an important contributor to progression of
chronichepatitis C. TheHIVenvelopeproteingp120blocks insulin sig-
nalingandvia inductionof oxidative stress increasesproﬁbrogenic tis-
sue inhibitor of metalloproteinase-1 (TIMP-1) in HCV-replicon cells,
and also directly induces procollagen synthesis in cultured HSC
[105–107].1034 Journal of Hepatology 2013Mechanisms of accelerated post-transplant liver ﬁbrosis in
hepatitis C
The character of the immune response to HCV signiﬁcantly deter-
mines ﬁbrosis progression. Importantly, the ﬁbrogenic response
is not simply dictated by the extent of histological cellular
inﬂammation, but rather by the chemokine and cytokine milieu
generated by the inﬂammatory environment. As a rule of thumb,
proinﬂammatory cells, such as classically activated (M1) macro-
phages, Th1 T cells, natural killer (NK) and invariant NK T (iNKT)
cells rather favour ﬁbrolysis, whereas cells that dampen chronic
inﬂammation, such as M2 macrophages, CD8+ T cells, regulatory
T cells (Treg) and often Th2 T cells suppress classical inﬂamma-
tion by production of proﬁbrogenic factors for activated HSC
and myoﬁbroblasts, such as TGFb1, IL13 or TIMP-1 [76,77,108–
113]. The latter group appears to include the Th17 T cell response
which has only recently been associated with liver ﬁbrosis pro-
gression [114]. While the wound healing response is often lim-
ited and leads to tissue restitution after elimination of the
pathogen, chronic hepatitis C generates a long-lasting low-level
inﬂammation. This creates the environment of a wound that does
not heal to be replaced by scar tissue. This paradigm also explains
why chronic comorbidities that further promote a reparative
immune response speed up liver ﬁbrogenesis in HCV infected
patients. Examples are co-infection with HIV (apart from the
above-mentioned direct effects of HIV-gp120), or Schistosoma
mansoni [115]. Much of the enhanced ﬁbrosis progression
observed in patients with chronic hepatitis C post-liver trans-
plant [1–4,18–21] is likely a consequence of similar alterations
due to immune suppression, although detailed studies are lack-
ing. Moreover, the already mentioned ‘‘second hits’’, especially
signiﬁcant alcohol abuse (as deﬁned by >20 g per day for females
and >30 g per day for males), fatty liver disease (NAFLD, NASH),vol. 58 j 1028–1041
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progression. This mechanism plays an important role in steatohepatitis, but
also in more advanced ﬁbrosis (especially FP2) and possibly in HCV post-
transplant ﬁbrosing cholestatic hepatitis, where massive virus replication and
hepatocyte apopotosis, likely favoured by other ‘‘second hits’’, such as vascular
compromise, steatosis, drug toxicity, elevated donor age and generation of
reactive oxygen species (ROS), e.g., due to prior ischemia reperfusion damage,
drive the emergence of ﬁbrogenic progenitor cells. These cells replicate ductal
plate formation by induction of a portal ﬁbrotic matrix via secretion of
proﬁbrogenic factors and recruitment and activation of myoﬁbroblasts (and
macrophages). On the other hand, these myoﬁbroblasts secrete factors and
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macrophage chemotactic peptide-1 (CCL-2); PDGF, platelet-derived growth
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JOURNAL OF HEPATOLOGYwith frequently associated insulin resistance, or hepatotoxic
medications, further damage hepatocytes, e.g., by inducing their
lipoapoptosis (Fig. 3).
Enhanced hepatocyte death, with associated proliferation of
ﬁbrogenic cholangiocytes and hepatic progenitor cells, appears
to underlie ﬁbrosing cholestatic hepatitis (FCH), the most severe
form of rapidly progressive post-transplant ﬁbrosis [29,116]. Pro-
liferation of cytokeratin 19 positive ﬁbrogenic progenitor cells is
triggered by hepatocyte growth arrest and apoptosis, and is a
hallmark not only of FCH, but also of advanced liver ﬁbrosis in
general [117–119] (Fig. 4). Of note, FCH occurs most frequently
in patients with severe repeated damage to hepatocytes, as recur-
rent rejection episodes, high viral replication and comorbidities
such as HIV-coinfection [28,120].
Genetic predisposition for HCV-induced ﬁbrosis
Genetic polymorphisms can partly explain the widely differing
individual rates of ﬁbrosis progression in chronic hepatitis C. This
has been demonstrated most convincingly for the liver ﬁbrosis
risk score that includes polymorphisms in 7 previously unsus-
pected genes and that has been validated as predictor of acceler-
ated ﬁbrosis progression in several cohorts of patients with
chronic hepatitis C [121,122], including patients post-transplant
[123]. For two of the genes affected, namely toll-like receptor 4Journal of Hepatology 2013and antizyme inhibitor 1, functional proof of a role in liver ﬁbro-
genesis has already been obtained [124,125], others are currently
subject to functional analysis. This risk score will be particularly
useful for stratiﬁcation of patients prior to studies with novel
(antiﬁbrotic) therapies [80,82].Effect of antiviral therapy on progression
Different treatment strategies are available for recurrent HCV
infection post-liver transplant. Treatment of established recur-
rent HCV infection with peginterferon (pIFN) and ribavirin
(RBV) leads to an overall SVR of 39%, ranging from 10% to 59%
[37–44]. The role of host and viral genetic factors and of the
immune suppressive regimens on the rate of sustained respond-
ers to antiviral therapy has been reviewed recently [2,37–
39,126–145]. In immune competent HCV-infected patients, per-
sistent viral clearance results in histological improvement and
in those treated at advanced stages of disease, SVR is associated
with improved clinical outcome with a signiﬁcantly lower risk
of developing HCC or clinical decompensation compared to
non-responders. The same appears to hold true in the liver trans-
plant setting, but randomized studies comparing long-term out-
come of treated vs. untreated patients are lacking (Table 4)
[38,40,41,131–150]. In the only study where patients with mild
hepatitis C recurrence (ﬁbrosis stage F0–F2, n = 54) were ran-
domized to no treatment (group A, n = 27) or peginterferon
alfa-2b/ribavirin for 48 weeks (group B, n = 27), liver ﬁbrosis pro-
gressed >1 stage in 19 subjects (70%) of group A vs. 7 (26%) subj-
cets of group B (p = 0.001). In that study, the only variable
independently associated with ﬁbrosis improvement/stabiliza-
tion was treatment (odds ratio [OR] 3.7, 95% conﬁdence interval
[CI] 1.3–10, p = 0.009) [41].
Importantly, in post-liver transplant patients, improvement in
inﬂammatory activity after viral eradication is well established,
but ﬁbrosis regression or stabilization is less predictable, and
usually not observed in the immediate post-treatment biopsy,
but rather in subsequent ‘‘long-term biopsies’’. In one study
based on 29 patients who had reached an SVR, ﬁbrosis at 2 years
improved by P1 Metavir stage in 27%, remained unchanged in
38%, and worsened in 35% despite viral clearance. At 3–5 years,
the ﬁbrosis stage had improved in 67%, remained unchanged in
13%, and worsened in 20% [146]. In another recent study, com-
parison of ﬁbrosis stage between pre-treatment and the last
post-treatment biopsy showed stabilization and/or improvement
in 57.5%, 75% in SVR compared to 50% of NR (p = 0.059). Interest-
ingly, while there were no differences in the number of biopsies
showing ﬁbrosis stabilization/improvement between end-of-
treatment and pre-treatment biopsies when comparing SVR and
NR (64% vs. 63%, p = 1), ﬁbrosis stabilization/improvement
became apparent when the biopsies performed at least
12 months post-treatment were compared to pre-treatment
biopsies (92% in SVR compared to 41% in NR; p = 0.005) [44]. In
several studies, favorable evolution of histological ﬁbrosis in suc-
cessfully treated HCV infected patients post-transplant correlated
with improvement in clinical end points, such as reduced HVPG,
less clinical decompensation and an increase of graft and patient
survival [42,44,132,146–150]. In one study where patient sur-
vival was compared between a cohort of 89 treated recipients
with IFN-based therapies and a matched control group of
untreated patients, survival was higher in the former than invol. 58 j 1028–1041 1035
Table 4. Changes in necroinﬂammatory grade and ﬁbrosis stage in HCV infected liver transplant recipients treated with interferon-based therapy.
Author; [Ref.] N treated SVR n (%) Changes in activity
Rodriguez-Luna et al., [126] 19 5 (26) SVR:
Improvement in 60%
Unchanged in 20%, 
Worse in 20%
SVR: improvement in 100%
NR: improvement in 40%
Neff et al., [127] 57 8 (14) 39 patients with paired biopsies:
Improvement (18) 
Unchanged (10)
Worse (11)
n.a.
Ross et al., [128] 16 0 (0) 9 patients with paired biopsies:
Unchanged (2)
Worse (7)
n.a.
Dumortier et al., [129] 20 9 (45) 2.2 to 1.6 1.8 to 0.3
Toniutto et al., [130] 12 1 (8) Unchanged in 6 (50%) Improvement in 3 (25%)
Biselli et al., [131] 20 9 (45) Improvement in 4/9
Berenguer et al., [132] 67 22 (33) 38 patients with paired biopsies:
SVR (n = 10)
Improvement (2)
Unchanged (4)
Worse (4)
NR (n = 28)
Improvement (4)
Unchanged (13)
Worse (11)
SVR (n = 10)
Improvement (6)
Unchanged (3)
Worse (1)
NR (n = 28)
Improvement (10)
Unchanged (10)
Worse (8)
Oton et al., [133] 55 24 (44) 15 patients with paired biopsies:
SVR: 2.4 ± 1.9 to 2.6 ± 1.3
NR: 2.7 ± 1.7 to 3.7 ± 1.6
SVR: HAI: 7.5 ± 2.1 to 3.3 ± 2.8 
NR: HAI: 7.1 ± 1.1 to 5.3 ± 3.2
Mukherjee et al., [134] 32 11 (34.3) 15 patients with paired biopsies:
Improvement (1) 
Unchanged (6) 
Worse (8)
n.a.
Mukherjee et al., [135] 39 13 (33.3) Improvement (4) 
Unchanged (10) 
Worse (3)
n.a.
Fernandez et al., [136] 47 11 (23) 16 patients with paired biopsies:
SVR (n = 7): 1.5 ± 1.1 to 1.16 ± 1.0
NR (n = 9): 2.4 to 2.8
SVR
PI: 2.3 ± 0.7 to 1.3 ± 0.7
LI: 2.8 ± 0.7 to 0.8 ± 0.9 
NR
No changes in HAI 
PI: 2.2-2.4
LI: 2.3-2.1
Neumann et al., [137] 25 9 (36) 1.7 to 2.0 1.66 to 1.13
Angelico et al., [138] 21 7 (33) 10 patients with paired biopsies:
Improvement (2)
Worse (7)
Improvement (2/10)
Worse (2/10)
Carrion et al., [41] 54 18 (33) Improvement (11)
Unchanged (22)
Worse (21)
n.a.
Hanouneh et al., [139] 53 19 (35) 18 patients with paired biopsies:
2 (1-2) to 2.5 (1-3)
Unchanged
Roche et al., [40] 113 54 (38) 81 patients with paired biopsies: 
SVR (n = 42): 2.3 ± 1.0 to 2.2 ± 1.3
Improvement (11) 
Unchanged (22) 
Worse (9)
NR (n = 39): 2.0 ± 0.9 to 2.4 ± 1.0
Unchanged (18) 
Worse (17)
SVR: 1.9 ± 0.6 to 1.0 ± 0.6
NR: 1.9 ± 0.7 to 1.4 ± 0.6
Changes in fibrosis
No significant change
SVR, sustained viral response; NR, non-response; HAI, hepatic activity index; LI, lobular inﬂammation; PI, portal inﬂammation; n.a., not available.
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Table 5. Antiﬁbrotic agents in clinical studies.
Company Drug
BMS-Amira: Am152: LPA1R-antagonist
Biogen-Stromedix: STX-100: α-Integrin αVβ6 mAb
Boehringer-Ingelheim: Nintendanib (BIBF1120): poly-Tyk-
inhibitor
Celgene: JNK-inhibitor
Gilead-Arresto: GS6624 (AB0024): α-Loxl2 mAb
Intermune: Pirfenidon: Growth factor antagonist
Janssen: Carlumab: α-MCP-1/CCL2 mAb
miRAGEN α-micro-RNA29
Novartis: QUAX576: α-IL-13 mAb
EXC001: CTGF-antisense DNA
FG3019: α-CTGF mAb
Promedior: RM-151: recombinant Pentraxin-2 
(SAP)
SAR156597: α-IL-4/IL-13 mAb
Fresolimumab: α-TGFβ mAb
Pfizer-Excaliard:
Pfizer-Fibrogen:
Sanofi-Genzyme:
Sanofi:
From: http://clinicalstudies.info.nih.gov/.
Tyk, tyrosine kinase; CTGF, connective tissue growth factor; JNK, Jun-N-terminal
kinase; mAb, monoclonal antibody; Loxl2, lysyl oxidase; LPA1R, lysophosphatidic
acid-1 receptor; MCP-1, macrophage chemotactic protein-1.
JOURNAL OF HEPATOLOGYthe latter group (7-year follow up: 74% vs. 62%; p = 0.04). In addi-
tion, among treated patients, all outcome variables (liver
enzymes, mortality rate, development of cirrhosis, decompensa-
tion of cirrhosis) were worse for non-responders compared to
those who had achieved SVR [150]. In patients who have cleared
the virus but continue to have altered liver function tests, a post-
treatment liver biopsy is warranted, in order to exclude rejection,
de novo autoimmune hepatitis or other concomitant pathologies
[35,36]. Whether in patients who achieve an SVR together with
a complete biochemical response, a follow-up liver biopsy 2–
5 years after treatment completion is still required or whether
non-invasive monitoring tools are sufﬁcient is still an open ques-
tion. The high efﬁcacy of novel interferon-free drugs (DAA, direct
acting antivirals) promises to offer hope for patients with post-
transplant aggressive recurrence [151] and it is likely that the
same beneﬁts in terms of ﬁbrosis regression and survival will
be achieved with these new drugs.Antiﬁbrotic therapy
A speciﬁc antiﬁbrotic therapy will be required in patients who do
not clear the virus, and/or who have additional risk factors for
ﬁbrosis progression. For many years, the clinical development
of antiﬁbrotic therapies had stalled, mainly due to the lack of
(1) appropriate targets, (2) antiﬁbrotic agents with high speciﬁc-
ity and an acceptable side-effect proﬁle, and (3) sensitive and
speciﬁc biomarkers or imaging technologies that reﬂect hepatic
ﬁbrosis and especially ﬁbrogenesis. Thus, only 4 major studies
were performed in CHC, with biopsy proven ﬁbrosis progression
as primary end point, testing IL-10, interferon-c, a glitazone and
interferon-a, all of them with disappointing results [152–155],
stressing the need for an optimized preclinical testing prior to
translation into the clinic [80,82]. However, the ﬁeld has gained
steam subsequent to an increasing number of promising targets
and drugs from high-quality preclinical studies, the ongoing
development and validation of improved biomarkers, and imag-Journal of Hepatology 2013ing modalities of ﬁbrosis and ﬁbrogenesis, and an increasing
interest of small and big pharma in the potentially vast antiﬁbrot-
ics market [76–78,80,82,152–160].
Table 5 lists some of the most promising antiﬁbrotic targets
and agents for which placebo-controlled clinical studies, includ-
ing as few as 60 and 200 patients, are planned or considered,
many of them in liver ﬁbrosis. Apart from conventional parame-
ters (liver histology, serum parameters), these studies use, to a
varying extent, improved biopsy readouts (such as quantitation
of ﬁbrosis-related gene expression, histomorphometry for ﬁbro-
sis and histological markers of ﬁbrogenesis), panels of surrogate
serum markers of liver ﬁbrosis and ﬁbrogenesis, ultrasound or
MR elastography of the liver, or functional testing like portal-
hepatic vein pressure gradient in cirrhotics or breath tests to
assess liver metabolic capacity. Notably, patients with post-trans-
plant HCV infection who often show rapid ﬁbrosis progression
are currently considered prime study subjects for short-term
(6–12 months) proof-of-concept trials for antiﬁbrotic agents.Financial support
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